-
Innovative TCM Xiao’er Huangjin Zhike Granules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Xiao' er Huangjin Zhike Granules of Beijing Dongfang Yunjia Pharmaceutical Co., Ltd. is approved for marketing through the priority review and approval procedure by China NMPA.
-
Recaticimab for Injection Approved for Marketing by China NMPA
2025-06-11
Recently, the Recaticimab for Injection (trade name: 艾心安) of Guangdong Hengrui Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Prusogliptin Tablets Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Prusogliptin Tablets (trade name: 善泽平) of CSPC OUYI PHARMACEUTICAL CO., LTD. is approved for marketing by China NMPA.
-
Innovative TCM Qifang Bitong Tablets Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Qifang Bitong Tablets of Beijing Yiling Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Limertinib Tablets Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Limertinib Tablets (trade name: 奥壹新) of Jiangsu Osaikang Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
-
Senaparib Capsules Approved for Marketing by China NMPA
2025-06-11
Recently, the Class 1 innovative drug Senaparib Capsules (trade name: 派舒宁/Paishuning) of Shanghai Inpai Pharmaceutical Co., Ltd. is approved for marketing by China NMPA.
